Eli Lilly (LLY) is targeting additional drug compounders and telehealth companies that make copycat versions of its weight loss drug, with ...

Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy will have the option to buy now and pay later under a partnership announced Tuesday by ...

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and Mounjaro.

The integration makes the fulfillment experience for single-dose vials of Eli Lilly and Company’s Zepbound® (tirzepatide) obesity medication more convenient and transparent for clinically ...

New integration means streamlined ordering and paying experiences for patients, with the same direct shipping and the best self-pay price on single-dose Zepbound vials NEW YORK CITY, March 24, 2025 ...

A month ago, Lilly unveiled $499 offerings of its rival weight-loss drug Zepbound exclusively through the company’s LillyDirect Self Pay Pharmacy Solutions. Since then, the Indianapolis pharma ...

With a FDA deadline set for March 26 to stop compounding versions of Zepbound, followed by restrictions on compounded Ozempic and Wegovy set for later this spring, the agency is meeting resistance ...

Eli Lilly has benefitted from the windfall from tirzepatide – the active ingredient in its weight loss injection Zepbound and diabetes shot Mounjaro – which targets GLP-1 but also activates ...

Both results wiped significant value from Novo's share price as investors' hopes of finding a superior alternative to the company's existing Wegovy injection and rival Eli Lily's Zepbound ...